- Home
- STG vs AGEN Comparison
STG vs AGEN Comparison
Compare STG & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STG
- AGEN
- Stock Information
- Founded
- STG 2003
- AGEN 1994
- Country
- STG China
- AGEN United States
- Employees
- STG N/A
- AGEN N/A
- Industry
- STG Other Consumer Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STG Real Estate
- AGEN Health Care
- Exchange
- STG Nasdaq
- AGEN Nasdaq
- Market Cap
- STG 91.6M
- AGEN 96.2M
- IPO Year
- STG 2018
- AGEN 2000
- Fundamental
- Price
- STG $6.16
- AGEN $3.32
- Analyst Decision
- STG
- AGEN Buy
- Analyst Count
- STG 0
- AGEN 3
- Target Price
- STG N/A
- AGEN $10.50
- AVG Volume (30 Days)
- STG 5.7K
- AGEN 360.9K
- Earning Date
- STG 03-21-2025
- AGEN 03-13-2025
- Dividend Yield
- STG N/A
- AGEN N/A
- EPS Growth
- STG N/A
- AGEN N/A
- EPS
- STG 4.57
- AGEN N/A
- Revenue
- STG $292,030,936.00
- AGEN $160,427,000.00
- Revenue This Year
- STG N/A
- AGEN N/A
- Revenue Next Year
- STG N/A
- AGEN $26.02
- P/E Ratio
- STG $1.35
- AGEN N/A
- Revenue Growth
- STG N/A
- AGEN 59.00
- 52 Week Low
- STG $4.25
- AGEN $2.50
- 52 Week High
- STG $12.55
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- STG 43.15
- AGEN 45.96
- Support Level
- STG $6.46
- AGEN $3.09
- Resistance Level
- STG $6.78
- AGEN $3.68
- Average True Range (ATR)
- STG 0.15
- AGEN 0.25
- MACD
- STG -0.06
- AGEN -0.03
- Stochastic Oscillator
- STG 1.30
- AGEN 23.00
About STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).